{"transactions":[{"id":3350121,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-06T22:15:06.000Z","date":"2019-12-04","kind":"sale","acquired":false,"shares":1000,"price":4.79,"value":4790.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-059516","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119059516/doc4.xml","form_type":"4"}},{"id":3405276,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-27T21:18:42.000Z","date":"2019-09-25","kind":"sale","acquired":false,"shares":3470,"price":5.31,"value":18425.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.20, inclusive."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001209191-19-051031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119051031/doc4.xml","form_type":"4"}},{"id":3405275,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-27T21:18:42.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":4400,"price":5.27,"value":23188.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.31 to $5.21, inclusive."}],"balance_after":4470,"source":{"system":"sec-edgar","filing":"0001209191-19-051031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119051031/doc4.xml","form_type":"4"}},{"id":3405274,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-27T21:18:42.000Z","date":"2019-09-20","kind":"sale","acquired":false,"shares":3700,"price":5.31,"value":19647.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.25, inclusive."}],"balance_after":8870,"source":{"system":"sec-edgar","filing":"0001209191-19-051031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119051031/doc4.xml","form_type":"4"}},{"id":3409224,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:16:58.000Z","date":"2019-09-19","kind":"sale","acquired":false,"shares":4000,"price":5.21,"value":20840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.13, inclusive."}],"balance_after":12170,"source":{"system":"sec-edgar","filing":"0001209191-19-050361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119050361/doc4.xml","form_type":"4"}},{"id":3409223,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:16:58.000Z","date":"2019-09-18","kind":"sale","acquired":false,"shares":2987,"price":4.95,"value":14785.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.05 to $4.81, inclusive."}],"balance_after":16170,"source":{"system":"sec-edgar","filing":"0001209191-19-050361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119050361/doc4.xml","form_type":"4"}},{"id":3409222,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:16:58.000Z","date":"2019-09-17","kind":"sale","acquired":false,"shares":711,"price":4.91,"value":3491.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":19157,"source":{"system":"sec-edgar","filing":"0001209191-19-050361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119050361/doc4.xml","form_type":"4"}},{"id":3409221,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:16:58.000Z","date":"2019-09-16","kind":"sale","acquired":false,"shares":100,"price":5.05,"value":505.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":19868,"source":{"system":"sec-edgar","filing":"0001209191-19-050361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119050361/doc4.xml","form_type":"4"}},{"id":3409220,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-20T21:16:58.000Z","date":"2019-09-13","kind":"sale","acquired":false,"shares":3117,"price":5.11,"value":15927.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.08, inclusive."}],"balance_after":19968,"source":{"system":"sec-edgar","filing":"0001209191-19-050361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119050361/doc4.xml","form_type":"4"}},{"id":3415294,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T21:27:31.000Z","date":"2019-09-12","kind":"sale","acquired":false,"shares":2646,"price":5.15,"value":13626.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.13, inclusive."}],"balance_after":23085,"source":{"system":"sec-edgar","filing":"0001209191-19-049507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119049507/doc4.xml","form_type":"4"}},{"id":3415293,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T21:27:31.000Z","date":"2019-09-11","kind":"sale","acquired":false,"shares":2700,"price":5.01,"value":13527.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.06 to $4.96, inclusive."}],"balance_after":25731,"source":{"system":"sec-edgar","filing":"0001209191-19-049507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119049507/doc4.xml","form_type":"4"}},{"id":3415292,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T21:27:31.000Z","date":"2019-09-10","kind":"sale","acquired":false,"shares":1400,"price":5.39,"value":7546.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.40 to $5.34, inclusive."}],"balance_after":28431,"source":{"system":"sec-edgar","filing":"0001209191-19-049507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119049507/doc4.xml","form_type":"4"}},{"id":3415291,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T21:27:31.000Z","date":"2019-09-09","kind":"sale","acquired":false,"shares":2300,"price":5.24,"value":12052.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.40 to $4.90, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.39 to $5.11, inclusive."}],"balance_after":29831,"source":{"system":"sec-edgar","filing":"0001209191-19-049507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119049507/doc4.xml","form_type":"4"}},{"id":3415290,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-13T21:27:31.000Z","date":"2019-09-06","kind":"sale","acquired":false,"shares":400,"price":4.91,"value":1964.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":32131,"source":{"system":"sec-edgar","filing":"0001209191-19-049507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119049507/doc4.xml","form_type":"4"}},{"id":3426121,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-30T21:18:43.000Z","date":"2019-08-30","kind":"sale","acquired":false,"shares":900,"price":5.11,"value":4599.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.12 to $5.07, inclusive."}],"balance_after":32531,"source":{"system":"sec-edgar","filing":"0001209191-19-047851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047851/doc4.xml","form_type":"4"}},{"id":3426120,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-30T21:18:43.000Z","date":"2019-08-28","kind":"sale","acquired":false,"shares":200,"price":5.02,"value":1004.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":33431,"source":{"system":"sec-edgar","filing":"0001209191-19-047851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047851/doc4.xml","form_type":"4"}},{"id":3426119,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-30T21:18:43.000Z","date":"2019-08-27","kind":"sale","acquired":false,"shares":100,"price":5.11,"value":511.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":33631,"source":{"system":"sec-edgar","filing":"0001209191-19-047851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047851/doc4.xml","form_type":"4"}},{"id":3426118,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-30T21:18:43.000Z","date":"2019-08-26","kind":"sale","acquired":false,"shares":1400,"price":5.16,"value":7224.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.15, inclusive."}],"balance_after":33731,"source":{"system":"sec-edgar","filing":"0001209191-19-047851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047851/doc4.xml","form_type":"4"}},{"id":3426117,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-30T21:18:43.000Z","date":"2019-08-23","kind":"sale","acquired":false,"shares":500,"price":5.33,"value":2665.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.30, inclusive."}],"balance_after":35131,"source":{"system":"sec-edgar","filing":"0001209191-19-047851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047851/doc4.xml","form_type":"4"}},{"id":3430365,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T20:56:06.000Z","date":"2019-08-21","kind":"sale","acquired":false,"shares":2100,"price":5.45,"value":11445.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":35631,"source":{"system":"sec-edgar","filing":"0001209191-19-047327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047327/doc4.xml","form_type":"4"}},{"id":3430364,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T20:56:06.000Z","date":"2019-08-20","kind":"sale","acquired":false,"shares":2631,"price":5.41,"value":14233.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.38, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.38, inclusive."}],"balance_after":37731,"source":{"system":"sec-edgar","filing":"0001209191-19-047327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047327/doc4.xml","form_type":"4"}},{"id":3430363,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T20:56:06.000Z","date":"2019-08-19","kind":"sale","acquired":false,"shares":1000,"price":5.45,"value":5450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":40362,"source":{"system":"sec-edgar","filing":"0001209191-19-047327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047327/doc4.xml","form_type":"4"}},{"id":3430362,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T20:56:06.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":500,"price":5.71,"value":2855.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.38, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.69, inclusive."}],"balance_after":41362,"source":{"system":"sec-edgar","filing":"0001209191-19-047327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047327/doc4.xml","form_type":"4"}},{"id":3430361,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-23T20:56:06.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":78,"price":5.75,"value":448.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."}],"balance_after":41862,"source":{"system":"sec-edgar","filing":"0001209191-19-047327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119047327/doc4.xml","form_type":"4"}},{"id":3436617,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-13","kind":"sale","acquired":false,"shares":1300,"price":5.75,"value":7475.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F10","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.76 to $5.75, inclusive."}],"balance_after":41940,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436616,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-12","kind":"sale","acquired":false,"shares":900,"price":5.75,"value":5175.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.75, inclusive."}],"balance_after":43240,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436615,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-09","kind":"sale","acquired":false,"shares":188,"price":5.79,"value":1088.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.76, inclusive."}],"balance_after":44140,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436614,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-08","kind":"sale","acquired":false,"shares":502,"price":6.01,"value":3017.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.08 to $5.95, inclusive."}],"balance_after":44328,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436613,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-07","kind":"sale","acquired":false,"shares":700,"price":5.98,"value":4186.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.04 to $5.95, inclusive."}],"balance_after":44830,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436612,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-05","kind":"sale","acquired":false,"shares":1500,"price":6.08,"value":9120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.10 to $6.05, inclusive."}],"balance_after":45530,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436611,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-02","kind":"sale","acquired":false,"shares":400,"price":6.07,"value":2428.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $6.00, inclusive."}],"balance_after":47030,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3436610,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T21:11:28.000Z","date":"2019-08-01","kind":"sale","acquired":false,"shares":800,"price":5.96,"value":4768.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.01 to $5.91, inclusive."}],"balance_after":47430,"source":{"system":"sec-edgar","filing":"0001209191-19-046347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119046347/doc4.xml","form_type":"4"}},{"id":3449813,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-31","kind":"sale","acquired":false,"shares":1100,"price":5.91,"value":6501.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F11","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.90, inclusive."}],"balance_after":48230,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449812,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":644,"price":5.81,"value":3741.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F10","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.80, inclusive."}],"balance_after":49330,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449811,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-29","kind":"sale","acquired":false,"shares":424,"price":5.84,"value":2476.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.83, inclusive."}],"balance_after":49974,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449810,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-26","kind":"sale","acquired":false,"shares":500,"price":5.83,"value":2915.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.80, inclusive."}],"balance_after":50398,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449809,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-25","kind":"sale","acquired":false,"shares":500,"price":5.85,"value":2925.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.85, inclusive."}],"balance_after":50898,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449808,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-24","kind":"sale","acquired":false,"shares":900,"price":5.84,"value":5256.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.76, inclusive."}],"balance_after":51398,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449807,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-22","kind":"sale","acquired":false,"shares":200,"price":5.63,"value":1126.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.64 to $5.62, inclusive."}],"balance_after":52298,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449806,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-19","kind":"sale","acquired":false,"shares":104,"price":5.61,"value":583.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.61 to $5.62, inclusive."}],"balance_after":52498,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3449805,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T21:19:36.000Z","date":"2019-07-18","kind":"sale","acquired":false,"shares":500,"price":5.69,"value":2845.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.69 to $5.69, inclusive."}],"balance_after":52602,"source":{"system":"sec-edgar","filing":"0001209191-19-044309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119044309/doc4.xml","form_type":"4"}},{"id":3458706,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T21:24:25.000Z","date":"2019-07-17","kind":"sale","acquired":false,"shares":1000,"price":5.64,"value":5640.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.65 to $5.63, inclusive."}],"balance_after":53102,"source":{"system":"sec-edgar","filing":"0001209191-19-042799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119042799/doc4.xml","form_type":"4"}},{"id":3458705,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T21:24:25.000Z","date":"2019-07-16","kind":"sale","acquired":false,"shares":478,"price":5.76,"value":2753.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.79 to $5.71, inclusive."}],"balance_after":54102,"source":{"system":"sec-edgar","filing":"0001209191-19-042799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119042799/doc4.xml","form_type":"4"}},{"id":3458704,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T21:24:25.000Z","date":"2019-07-15","kind":"sale","acquired":false,"shares":2200,"price":5.69,"value":12518.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.77 to $5.67, inclusive."}],"balance_after":54580,"source":{"system":"sec-edgar","filing":"0001209191-19-042799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119042799/doc4.xml","form_type":"4"}},{"id":3458703,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T21:24:25.000Z","date":"2019-07-12","kind":"sale","acquired":false,"shares":2893,"price":5.89,"value":17039.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.80, inclusive."}],"balance_after":56780,"source":{"system":"sec-edgar","filing":"0001209191-19-042799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119042799/doc4.xml","form_type":"4"}},{"id":3458702,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-19T21:24:25.000Z","date":"2019-07-11","kind":"sale","acquired":false,"shares":900,"price":5.74,"value":5166.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.70, inclusive."}],"balance_after":59673,"source":{"system":"sec-edgar","filing":"0001209191-19-042799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119042799/doc4.xml","form_type":"4"}},{"id":3463098,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-10","kind":"sale","acquired":false,"shares":2300,"price":5.9,"value":13570.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.81, inclusive."}],"balance_after":60573,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463097,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-09","kind":"sale","acquired":false,"shares":500,"price":6.11,"value":3055.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.05, inclusive."}],"balance_after":62873,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463096,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-08","kind":"sale","acquired":false,"shares":400,"price":6.25,"value":2500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.32 to $6.20, inclusive."}],"balance_after":63373,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463095,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-05","kind":"sale","acquired":false,"shares":668,"price":6.31,"value":4215.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.30, inclusive."}],"balance_after":63773,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463094,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-03","kind":"sale","acquired":false,"shares":729,"price":6.32,"value":4607.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.35 to $6.28, inclusive."}],"balance_after":64441,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463093,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-02","kind":"sale","acquired":false,"shares":2802,"price":6.36,"value":17820.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.35, inclusive."}],"balance_after":65170,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463092,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":2788,"price":6.41,"value":17871.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $6.38, inclusive."}],"balance_after":67972,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463091,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-06-28","kind":"sale","acquired":false,"shares":2324,"price":6.37,"value":14803.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.31, inclusive."}],"balance_after":70760,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3463090,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:16:03.000Z","date":"2019-06-27","kind":"sale","acquired":false,"shares":1865,"price":6.35,"value":11842.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.31, inclusive."}],"balance_after":73084,"source":{"system":"sec-edgar","filing":"0001209191-19-041961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119041961/doc4.xml","form_type":"4"}},{"id":3476318,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T21:15:03.000Z","date":"2019-06-26","kind":"sale","acquired":false,"shares":1266,"price":6.4,"value":8102.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.44 to $6.38, inclusive."}],"balance_after":74949,"source":{"system":"sec-edgar","filing":"0001209191-19-039526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119039526/doc4.xml","form_type":"4"}},{"id":3476317,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T21:15:03.000Z","date":"2019-06-25","kind":"sale","acquired":false,"shares":2310,"price":6.44,"value":14876.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.40, inclusive."}],"balance_after":76215,"source":{"system":"sec-edgar","filing":"0001209191-19-039526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119039526/doc4.xml","form_type":"4"}},{"id":3476316,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T21:15:03.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":4000,"price":6.36,"value":25440.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.20, inclusive."}],"balance_after":78525,"source":{"system":"sec-edgar","filing":"0001209191-19-039526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119039526/doc4.xml","form_type":"4"}},{"id":3476315,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T21:15:03.000Z","date":"2019-06-21","kind":"sale","acquired":false,"shares":3794,"price":6.22,"value":23598.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.15, inclusive."}],"balance_after":82525,"source":{"system":"sec-edgar","filing":"0001209191-19-039526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119039526/doc4.xml","form_type":"4"}},{"id":3476314,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T21:15:03.000Z","date":"2019-06-20","kind":"sale","acquired":false,"shares":1894,"price":6.19,"value":11723.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive."}],"balance_after":86319,"source":{"system":"sec-edgar","filing":"0001209191-19-039526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119039526/doc4.xml","form_type":"4"}},{"id":3481697,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:26:37.000Z","date":"2019-06-19","kind":"sale","acquired":false,"shares":1610,"price":6.19,"value":9965.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive."}],"balance_after":88213,"source":{"system":"sec-edgar","filing":"0001209191-19-038591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119038591/doc4.xml","form_type":"4"}},{"id":3481696,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:26:37.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":1656,"price":6.22,"value":10300.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.19, inclusive."}],"balance_after":89923,"source":{"system":"sec-edgar","filing":"0001209191-19-038591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119038591/doc4.xml","form_type":"4"}},{"id":3481695,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:26:37.000Z","date":"2019-06-17","kind":"sale","acquired":false,"shares":2050,"price":6.19,"value":12689.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive."}],"balance_after":91479,"source":{"system":"sec-edgar","filing":"0001209191-19-038591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119038591/doc4.xml","form_type":"4"}},{"id":3481694,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:26:37.000Z","date":"2019-06-14","kind":"sale","acquired":false,"shares":1859,"price":6.24,"value":11600.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.20, inclusive."}],"balance_after":93529,"source":{"system":"sec-edgar","filing":"0001209191-19-038591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119038591/doc4.xml","form_type":"4"}},{"id":3481693,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-21T21:26:37.000Z","date":"2019-06-13","kind":"sale","acquired":false,"shares":1701,"price":6.25,"value":10631.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.20, inclusive."}],"balance_after":95388,"source":{"system":"sec-edgar","filing":"0001209191-19-038591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119038591/doc4.xml","form_type":"4"}},{"id":3490219,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":1462,"price":6.11,"value":8932.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F14","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.21 to $6.11, inclusive."}],"balance_after":97089,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490218,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-11","kind":"sale","acquired":false,"shares":942,"price":6.21,"value":5849.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F13","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive."}],"balance_after":98551,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490217,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-10","kind":"sale","acquired":false,"shares":3549,"price":6.03,"value":21400.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F12","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.12 to $5.90, inclusive."}],"balance_after":99493,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490216,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-07","kind":"sale","acquired":false,"shares":2278,"price":5.99,"value":13645.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F11","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.86, inclusive."}],"balance_after":103042,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490215,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-06","kind":"sale","acquired":false,"shares":1495,"price":6.22,"value":9298.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F10","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.29 to $6.15, inclusive."}],"balance_after":105320,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490214,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-05","kind":"sale","acquired":false,"shares":2500,"price":6.55,"value":16375.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $6.43, inclusive."}],"balance_after":106815,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490213,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-04","kind":"sale","acquired":false,"shares":1300,"price":6.46,"value":8398.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.55 to $6.37, inclusive."}],"balance_after":109315,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490212,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-06-03","kind":"sale","acquired":false,"shares":1120,"price":6.33,"value":7089.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.25, inclusive."}],"balance_after":110615,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490211,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-05-31","kind":"sale","acquired":false,"shares":742,"price":6.46,"value":4793.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.48 to $6.45, inclusive."}],"balance_after":111735,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490210,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-05-30","kind":"sale","acquired":false,"shares":663,"price":6.46,"value":4282.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.43, inclusive."}],"balance_after":112477,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490209,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":1800,"price":6.38,"value":11484.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.33, inclusive."}],"balance_after":113140,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3490208,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:22:06.000Z","date":"2019-05-28","kind":"sale","acquired":false,"shares":3789,"price":6.44,"value":24401.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.  This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive.  The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $6.55 to $6.26, inclusive."}],"balance_after":114940,"source":{"system":"sec-edgar","filing":"0001209191-19-037202","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919119037202/doc4.xml","form_type":"4"}},{"id":3984184,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T21:44:08.000Z","date":"2018-03-23","kind":"grant","acquired":true,"shares":1000,"price":6.7,"value":6700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock award will vest 100% on March 20, 2019."}],"balance_after":118729,"source":{"system":"sec-edgar","filing":"0001209191-18-021475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919118021475/doc4.xml","form_type":"4"}},{"id":4356250,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":153296,"kind":"person","name":"Bernard Gordon R","position":1,"cik":"0001470015","reported_name":"Bernard Gordon R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-07T21:02:09.000Z","date":"2017-04-07","kind":"grant","acquired":true,"shares":1000,"price":6.45,"value":6450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock award will vest 100% on March 17, 2018."}],"balance_after":117729,"source":{"system":"sec-edgar","filing":"0001209191-17-026317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919117026317/doc4.xml","form_type":"4"}}]}